User:Mr. Ibrahem/Rilonacept
| Clinical data | |
|---|---|
| Trade names | Arcalyst |
| Other names | IL-1 Trap |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Subcutaneous |
| Drug class | Interleukin 1 receptor inhibitor[1] |
| Legal status | |
| Legal status | |
| Chemical and physical data | |
| Formula | C9030H13932N2400O2670S74 |
| Molar mass | 201209.36 g·mol−1 |
  (what is this?) (verify) | |
Rilonacept, sold under the brand name Arcalyst, is a medication used to treat cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome, and Muckle–Wells syndrome; deficiency of interleukin-1 receptor antagonist; and recurrent pericarditis.[2] It is given by injection under the skin.[2]
Common side effects pain at the site of injection and respiratory tract infection.[2] Other side effects may include infections, cancer, and allergic reactions.[2][1] There are concerns that use in pregnancy could harm the baby.[4] It is an interleukin 1 receptor inhibitor.[1]
Rilonacept was approved for medical use in the United States in 2008.[1] While it was approved in Europe in 2009, this approval was withdrawn in 2012.[5] In the United States, four vials of 220 mg cost about 21,000 USD as of 2021.[6]
References[edit]
- ^ a b c d "Rilonacept Monograph for Professionals". Drugs.com. Archived from the original on 12 August 2020. Retrieved 17 October 2021.
- ^ a b c d e f g "Arcalyst- rilonacept injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 16 January 2021. Retrieved 18 March 2021.
- ^ "Rilonacept Regeneron (previously Arcalyst) EPAR". European Medicines Agency (EMA). Archived from the original on 2 March 2021. Retrieved 18 March 2021.
- ^ "Rilonacept (Arcalyst) Use During Pregnancy". Drugs.com. Archived from the original on 25 January 2021. Retrieved 17 October 2021.
- ^ "Rilonacept Regeneron (previously Arcalyst)". Archived from the original on 2 March 2021. Retrieved 17 October 2021.
- ^ "Arcalyst Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 24 November 2020. Retrieved 17 October 2021.